Bacteroides fragilis is a genus of anaerobic bacteria that is normal in humans, and is classified as gram-negative. As such, Bacteroides fragilis infection is known to pose great risks to human health as it can basically be triggered with great ease. These are in the category that exceeds human health tolerance, and hence a vaccine and therapy for Bacteroides fragilis infection is being invented. It goes without saying that our firm is a world class research service provider and as such, we do have options in this region.
Overview of Bacteroides Fragilis Infection
Bacteroides fragilis is a highly adaptable bacterium which has the ability to be a commensal organism as well as an opportunistic pathogen. According to its primary function B. fragilis is a commensal bacterium since it contributes to metabolic activity in the human gut of healthy individuals. On the other hand, altering of the gut microbiota or the immunocompromised state of the B. fragilis can enable infection. A strain of the organism, ETBF, secretes fragilysin, a diarrhea-inducing toxin that causes inflammation and may promote colorectal cancer.
Pathogenesis of Bacteroides Fragilis Infection
The Bacteroides fragilis infection, specifically ETBF, has a complex array of causes and causes. ETBF creates a fragilysin toxin which has been shown to slash E-cadherin which results in the free catenins accumulation in the free cytosol. Consequently, the Tcf-dependent β-catenin nuclear signalling pathways are turned on which are capable of inducing the oncotypic changes in the intestinal cells. Additionally, diarrhea and inflammation which are also the characteristics of ETBF contribute to its pathogenicity as well.
Fig. 1 Enterotoxigenic Bacteroides fragilis (ETBF) infection enhances colonic tumorigenesis in the AOM/DSS model. (Hwang S., et al., 2020)
Vaccine Development for Bacteroides Fragilis Infection
The colonization and active infection can be avoided with the help of the Immune system, automatic response caused by the presence of B. fragilis is the reason vaccines are developed. The immunogenic components of scope of fragilis polysaccharide capsules has recently become an area in the industry to focus on.
Moving on to vaccine development, B. fragilis' polysaccharide capsule has been in the spotlight due to some conducting the research. It has already been recognized that antibodies against the capsule protect against the B fragilis infection. Additionally, they ascertain PSA (polysaccharide A) as a specific candidate for the polysaccharide in A vaccine for B. fragilis.
Therapeutics Development for Bacteroides Fragilis Infection
The first metronidazole a commonly prescribed antibiotic suitable for anaerobic bacteria including B. fragilis is the drug of choice for B. fragilis infections. However, there are situations that are exceptions and need alternative therapeutics where in this case metronidazole is useless. MoA - metronidazole resistant B fragilis is sensitive to cefoxitin, moxifloxacin and clindamycin along with piperacillin/tazobactam, meropenem and tazobactam/ceftolozane for complicated infections like in case of peritonitis with Bacteroides fragilis.
As such, efforts are made to discover new antibiotics and investment techniques that would enhance the therapy to patients infected by that pathogen. Our company participates in working out complex sets of measures for R&D aimed at development of new therapeutic agents for Bacteroides fragilis infection.
Our Services
Our team offers a comprehensive vaccine and therapy development service for Bacteroides fragilis infection in response to a wide range of therapies while addressing the complexities of this pathogen. In order to boost the development of vaccine and therapy, our team of skilled scientists and researchers makes use of advanced technologies and methodologies.
- Live-attenuated Vaccine
- Inactivated Vaccine
- Toxoid Vaccine
- Viral Vector Vaccine
- Virus-like Particles Vaccine
- Protein Subunit Vaccine
- mRNA Vaccine
- DNA Vaccine
- Small Molecule Drug Development Services
- Therapeutic mRNA Development Services
- Therapeutic Antibody Development Services
- Cell Therapy Development Services
- Bacteroides Fragilis Infection Models
Through various administration methods, such as oral gavage or rectal administration, Bacteroides fragilis strains can be introduced into the mice, simulating the infection process.
- AOM/DSS Mouse Models
- APCMin/+ Mouse Models
The process of creating Bacteroides fragilis infection vaccines and therapies would greatly benefit from preclinical research. We provide a wide range of preclinical research, which comes to include in vitro assays, animal studies and toxicology. For more details and a quote on the desired services, please do not hesitate to contact us.
References
- Hwang Soonjae, et al. "Enterotoxigenic Bacteroides fragilis infection exacerbates tumorigenesis in AOM/DSS mouse model." International Journal of Medical Sciences 17.2 (2020): 145.
- Elsaghir Hend, and Anil Kumar Reddy Reddivari. "Bacteroides fragilis." StatPearls [Internet]. StatPearls Publishing, 2023.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
